We hope that you've taken the opportunity to respond to our specimen integrity survey, which remains open for a few more days.
Mar 12, 2019 6:13pm
Mar 6, 2019 8:00am
The iSPOT study links treatment outcomes for acute isechemic stroke in hyperglycemic patients with markers of tissue factor pathway activation, as reported on March 5, 2019 in The Heart.org.
Mar 6, 2019 7:54am
The Heart.Org reports that the the Rivaroxaban and Apixaban reversal agent Andexxa (andexanet alpha) has earned conditional approval by the European Medicines Agency. Click or tap here for details.